SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-17386"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-17386" > EGFR, HER2 and HER3...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004042naa a2200469 4500
001oai:DiVA.org:uu-17386
003SwePub
008080623s2007 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-173862 URI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Wei, Qichunu Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Enheten för biomedicinsk strålningsvetenskap, Biomedical Radiation Sciences4 aut
2451 0a EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases
264 1c 2007
338 a print2 rdacarrier
520 a The expression of EGFR, HER2 and HER3 receptors were analyzed in immunohistochemical preparations from primary esophageal tumours and corresponding lymph node metastases. The goal was to evaluate whether any of these receptors are suitable as targets for radionuclide based imaging and therapy. The receptor expressions were evaluated in parallel samples, primary tumour and metastasiis, from each patient (n = 51). The majority of the cases were esophageal squamous cell carcinomas, ESCC, (n = 40). The HercepTest scoring was used for the analysis of both HER2 and EGFR expression (0, 1+, 2+ or 3+). HER3 was only evaluated as negative, weak or strong staining. EGFR overexpression (2+/3+) was found in 67.5 % (27/40) of both the ESCC primary tumours and the corresponding lymph node metastases. There were only a few changes in these EGFR-scores;: two cases from 2+/3+ to 0/1+ when the primary tumours were compared to the corresponding metastases and two changes the other way around. HER2 overexpression (2+/3+) was only found only in 3three of the primary ESCC tumours and 2two of the lymph node metastases. EGFR and HER2 stainings were found mainly in the cell membranes. The HER3 staining (weak or strong) was mainly cytoplasmic and granular and was observed in about half (20/39) of the cases, for both the ESCC primary tumours and the corresponding lymph node metastases. It is was concluded that ESCC lymph node metastases generally have a strong expression of EGFR stronglyin their cell membranes and to the same extent as in the primary tumours. The stability in EGFR expression is encouraging for efforts to develop radionuclide based EGFR imaging agents. It is also possible that EGFR targeting agents (e.g. Iressa, Tarceva, Erbitux or radiolabelled antibodies) can be applied for therapy of ESCC.
653 a Aged
653 a Carcinoma; Squamous Cell/*metabolism
653 a Esophageal Neoplasms/*metabolism
653 a Gene Expression Regulation; Neoplastic
653 a Humans
653 a Immunohistochemistry/methods
653 a Lymphatic Metastasis
653 a Middle Aged
653 a Neoplasm Metastasis
653 a Receptor; Epidermal Growth Factor/*metabolism
653 a Receptor; erbB-2/*metabolism
653 a Receptor; erbB-3/*metabolism
653 a MEDICINE
653 a MEDICIN
700a Chen, Lirong4 aut
700a Sheng, Liming4 aut
700a Nordgren, Hansu Uppsala universitet,Institutionen för genetik och patologi4 aut
700a Wester, Kennethu Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Enheten för biomedicinsk strålningsvetenskap, Biomedical Radiation Sciences4 aut0 (Swepub:uu)kennwest
700a Carlsson, Jörgenu Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Enheten för biomedicinsk strålningsvetenskap, Biomedical Radiation Sciences4 aut0 (Swepub:uu)jorgcarl
710a Uppsala universitetb Enheten för biomedicinsk strålningsvetenskap4 org
773t International Journal of Oncologyg 31:3, s. 493-499q 31:3<493-499x 1019-6439x 1791-2423
856u http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17671674&dopt=Citation
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-17386

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy